You just read:

Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark

News provided by

Relmada Therapeutics, Inc.

Jun 29, 2015, 08:00 ET